Multiple Myeloma (MM) research is at the forefront of personalized medicine, driven by rapid advancements in laboratory genomics and molecular diagnostics.
ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, ...
Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.
Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results